Biotechnology News and Research

RSS

Taligen Therapeutics announces closing on $10M tranche of Series B financing

Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has closed on a $10 million tranche of a Series B financing, based on substantial progress with the company's product pipeline including advancing the lead product candidate, TT30, toward clinical development.

23 Aug 2010

Applied Biosystems 3500 Dx Series Genetic Analyzers now available in Asia Pacific Region

Life Technologies Corporation today announced that its Applied Biosystems 3500 Dx Series Genetic Analyzers, the first CE IVD-marked capillary electrophoresis system for nucleic acid analysis, are now available for sale in Australia, India, New Zealand, Singapore, and Taiwan.

23 Aug 2010

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Alexion Pharmaceuticals, Inc. today announced that the US Food and Drug Administration (FDA) has approved Alexion's Rhode Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a second source of commercial supply for Soliris® (eculizumab).

23 Aug 2010

Castor bean genome may help prevent potential bioterrorism events

A research team co-led by scientists from the J. Craig Venter Institute (JCVI) and the Institute for Genome Sciences (IGS), University of Maryland School of Medicine, today published the sequence and analysis of the castor bean (Ricinus communis) genome in Nature Biotechnology.

23 Aug 2010

New antisense drugs may help treat accidental infections: Study

New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure-suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.

23 Aug 2010

Bottled tea contains less antioxidants, high sugar content

The first measurements of healthful antioxidant levels in commercial bottled tea beverages has concluded that health-conscious consumers may not be getting what they pay for: healthful doses of those antioxidants, or "poylphenols," that may ward off a range of diseases.

23 Aug 2010

Hepatitis E vaccine successful in clinical trial: Study

In a Clinical trial in China, a vaccine has been found to protect against Hepatitis E. Hepatitis E virus, usually spread via contaminated food and faeces usually runs its course before the patient recovers. However it can cause severe illness in elderly people and has a mortality rate of 1 to 3 percent. It can also kill 5 to 25 percent of affected pregnant women and those who survive can suffer high rates of miscarriage. Around a third of the world's population have been infected by the virus say researchers.

22 Aug 2010

BIO applauds release of HHS Public Health Emergency Medical Countermeasures Enterprise Review

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the Public Health Emergency Medical Countermeasures Enterprise Review released yesterday by Health and Human Services (HHS) Secretary Kathleen Sebelius.

21 Aug 2010

OMICS recommends three-step plan for sustainable advancement and innovation

The U.S. needs a comprehensive and transformational policy for the 21st century to ensure that it remains competitive in the global science and technology arena, according to a provocative opinion piece in the latest issue of OMICS, A Journal of Integrative Biology, a peer-reviewed journal published by Mary Ann Liebert, Inc.

21 Aug 2010

ChemAxon adds more predictions to chemistry browsing service

ChemAxon announces the addition of major new functionality in it's chemicalize.org web based service. The new features help users understand better the chemical structure with more predicted properties and a customizable layout to be of most use.

21 Aug 2010

USPTO to allow patent for Advaxis’s new vaccine technology

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has been notified that the US Patent and Trademark Office (USPTO) will allow a patent issuance of its application No. 11/785,249 entitled "Antibiotic Resistance Free Vaccines and Methods for Constructing and Using Same."

21 Aug 2010

SUNY Downstate Medical Center to provide content from 'Lippincott's Nursing Procedures and Skills' to nurses

Lippincott Williams & Wilkins announced today SUNY Downstate Medical Center, Brooklyn, New York, will provide the expert clinical content from Lippincott's Nursing Procedures and Skills to the nurses in their facility. Lippincott Williams & Wilkins is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy. SUNY Downstate Medical Center is one of the nation's leading urban medical centers, serving over 2.3 million people.

20 Aug 2010

Bavarian Nordic comments on Obama Administration's revised strategy for medical countermeasures

Bavarian Nordic A/S -- a leading industrial biotechnology company and long-term collaborator with the U.S. Government on the development of vaccines for the protection against biological threats, today commented on the Obama Administration's revised strategy for development, procurement and stockpiling of medical countermeasures.

20 Aug 2010

JCI to pay $188 million for fraudulently obtaining confidential information of Hemispherx

Johannesburg Consolidated Investments Limited, a South African-based investment and finance company, was recently ordered to pay $188 million to Hemispherx Biopharma Inc. a biopharmaceutical company, for fraudulently obtaining confidential and proprietary information.

20 Aug 2010

Cell-depleted lung used as natural growth matrix for generating new rat lung from embryonic stem cells

The first successful report of using cell-depleted lung as a natural growth matrix for generating new rat lung from embryonic stem cells is presented in a breakthrough article in Tissue Engineering, Part A, a peer-reviewed journal published by Mary Ann Liebert, Inc..

20 Aug 2010

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

International Stem Cell Corporation, today announced that its stem cell therapeutic programs focused on protective, transparent corneas (CytoCor™) in the front of the eye and the light-sensitive retinal tissue (CytoRet™) in the back of the eye will be formalized into a new business unit, Cytovis™.

20 Aug 2010

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

20 Aug 2010

PAREXEL International launches temperature recording solution optimized for clinical trial supply process

PAREXEL International Corporation, a leading global biopharmaceutical services organization, today announced that it has introduced an integrated temperature recording solution for study drug transportation as part of its expanded Clinical Logistics Services.

From Parexel 19 Aug 2010

MannKind Corporation enters into stock lending agreement with Bank of America

MannKind Corporation today announced that it has entered into a previously announced stock lending agreement pursuant to which it will lend 9,000,000 shares of its common stock to Bank of America, N.A. MannKind has also entered into an underwriting agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated ("Merrill Lynch"), an affiliate of Bank of America, pursuant to which Merrill Lynch will sell the shares at an offering price of $5.55 per share.

19 Aug 2010

MannKind Corporation announces pricing of Senior Convertible Notes due 2015

MannKind Corporation today announced the pricing of its previously announced offering of $100 million aggregate principal amount of Senior Convertible Notes due 2015 (the "Notes"). The Notes will be offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), by the financial institutions that are the initial purchasers of the notes.

19 Aug 2010

Biotechnology News and Research

Taligen Therapeutics announces closing on $10M tranche of Series B financing

Applied Biosystems 3500 Dx Series Genetic Analyzers now available in Asia Pacific Region

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Castor bean genome may help prevent potential bioterrorism events

New antisense drugs may help treat accidental infections: Study

Bottled tea contains less antioxidants, high sugar content

Hepatitis E vaccine successful in clinical trial: Study

BIO applauds release of HHS Public Health Emergency Medical Countermeasures Enterprise Review

OMICS recommends three-step plan for sustainable advancement and innovation

ChemAxon adds more predictions to chemistry browsing service

USPTO to allow patent for Advaxis’s new vaccine technology

SUNY Downstate Medical Center to provide content from 'Lippincott's Nursing Procedures and Skills' to nurses

Bavarian Nordic comments on Obama Administration's revised strategy for medical countermeasures

JCI to pay $188 million for fraudulently obtaining confidential information of Hemispherx

Cell-depleted lung used as natural growth matrix for generating new rat lung from embryonic stem cells

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

PAREXEL International launches temperature recording solution optimized for clinical trial supply process

MannKind Corporation enters into stock lending agreement with Bank of America

MannKind Corporation announces pricing of Senior Convertible Notes due 2015

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News